Asterias Biotherapeutics

Asterias Biotherapeutics is a development-stage biotechnology company pioneering the field of regenerative medicine. It focuses on the development of therapeutic products to treat neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases. It is also developing human embryonic stem cell programs, including cell lines and a Phase I clinical trial in patients with acute spinal cord injury; intellectual property related to its autologous cellular immunotherapy program, including a Phase I/II clinical trial of autologous immunotherapy in patients with acute myelogenous leukemia; and non-therapeutic applications of pluripotent stem cells, such as cellular assay products for use in drug development and toxicity screening.  The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California.

LISLE, Ill.--(BUSINESS WIRE)-- #astdelivers--AST Acquires Symatrix.

Applications Software Technology Acquires Symatrix to Accelerate Global Expansion in Oracle Cloud Services

LISLE, Ill.--( BUSINESS WIRE )--Applications Software Technology (AST), a leading digital transformation solutions provider, announced today the acquisition of Computer Technology Resources, Inc. (CTR) to further expand the breadth of AST's service offerings in the Oracle and adjacent cloud ecosystems.

News for Asterias Biotherapeutics Stock (AST)